Dell Technologies Inc vs Cassava Sciences Inc — how do they compare? Dell Technologies Inc trades at $584.66 (market cap $365.31B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Dell Technologies Inc is far larger — about 9271.8× Cassava Sciences Inc's market cap, and Dell Technologies Inc pays a 0.44% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Cassava Sciences Inc for 37 Days on average.
| DELL | FLNA | |
|---|---|---|
Market Cap | $365.31B | $39.40M |
Volume | 5,121,365 | 759,018 |
Sector | Technology | Health |
52-Week High | $588.67 | $4.64 |
52-Week Low | $111.10 | $0.68 |
Typical Hold Time | 57 Days | 37 Days |
Enterprise Value | $388.20B | -$43.28M |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $575.33, down 0.63% on the day, but maintains a bullish technical trend with strong support near $566. The stock is buoyed by robust AI server demand, with Q2 2026 EPS beating estimates by 43% and fiscal 2027 revenue guidance raised to approximately $192 billion. Recent news highlights a 20% dividend increase and a $74 billion AI server backlog, fueling investor optimism.
Outlook remains positive given explosive AI-driven growth, but risks include execution on massive orders and competitive pressures. Analysts are largely bullish with a $566.35 consensus target, though the current price slightly exceeds it. Shareholders should monitor margin sustainability and debt levels amid rapid expansion.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →